Personalized prophylaxis

Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight

(2011) S. Bjorkman et al.   BLOOD

Clinical severity of haemophilia A: does the classification of the 1950s still stand?

(2011) I. E. M. Den UIJL et al.   HAEMOPHILIA

A United Kingdom Haemophilia Centre Doctors’ Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A

(2010) Michael Richards et al.   BRITISH JOURNAL OF HAEMATOLOGY

Evaluation of the TCIWorks Bayesian computer program for estimation of individual pharmacokinetics of FVIII

(2010) S. BJÖRKMAN   HAEMOPHILIA

Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia

(2010) P. W. COLLINS et al.   HAEMOPHILIA

Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring

(2010) S. BJÖRKMAN et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study

(2009) P. COLLINS et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens

(2009) P. W. COLLINS et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A

(2008) P. W. COLLINS et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS